Literature DB >> 35471148

CBX3 regulated by miR-139 promotes the development of HCC by regulating cell cycle progression.

Pan Zhang1, Xiaoyan Yang1, Zhongming Zha2, Yumeng Zhu1, Guoqiang Zhang1,3, Guotao Li1.   

Abstract

Hepatocellular carcinoma (HCC), a major primary liver cancer, is one of the most lethal malignancies worldwide. Increasing evidence has demonstrated that chromobox protein homolog 3 (CBX3) functions as an oncogene in different cancers. However, its expression profiles and biological functions in HCC remain unknown. Data on CBX3 expression in HCC acquired from the GEO and TCGA databases were analyzed. The biological functions of CBX3 in HCC were examined by in vitro experiments. Bioinformatics analysis, qRT-PCR and western blotting were performed to explore the mechanism of CBX3 in HCC. CBX3 mRNA was upregulated in HCC tissues, and overexpression of CBX3 mRNA was negatively correlated with malignancies and poor prognosis in HCC patients. CBX3 knockdown decreased growth, migration and invasion of HCC cells in vitro. Moreover, bioinformatics analysis and experimental observation indicated that CBX3 expression was correlated with cell cycle regulatory proteins in HCC cells. Finally, starBase predicted that miR-139 could directly target CBX3 in HCC. Confirmatory experiments verified that miR-139 overexpression attenuated HCC cell proliferation and migration, and these effects could be reversed by overexpressing CBX3. Our results showed that the miR-139/CBX3 axis may be involved in HCC development by regulating cell cycle progression and may be a promising target in the treatment of HCC.

Entities:  

Keywords:  CBX3; HCC; cell cycle progression; miR-139

Mesh:

Substances:

Year:  2022        PMID: 35471148      PMCID: PMC9302499          DOI: 10.1080/15384101.2022.2068329

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  32 in total

Review 1.  MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

Authors:  Hui Ling; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2013-11       Impact factor: 84.694

Review 2.  MicroRNAs in cancer: biomarkers, functions and therapy.

Authors:  Josie Hayes; Pier Paolo Peruzzi; Sean Lawler
Journal:  Trends Mol Med       Date:  2014-07-12       Impact factor: 11.951

Review 3.  Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.

Authors:  Donald Poon; Benjamin O Anderson; Li-Tzong Chen; Koichi Tanaka; Wan Yee Lau; Eric Van Cutsem; Harjit Singh; Wan Cheng Chow; London Lucien Ooi; Pierce Chow; Maung Win Khin; Wen Hsin Koo
Journal:  Lancet Oncol       Date:  2009-11       Impact factor: 41.316

4.  CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non-small cell lung cancer.

Authors:  Shih-Chieh Chang; Yi-Chun Lai; Yen-Chung Chen; Nai-Kuan Wang; Wei-Shu Wang; Jiun-I Lai
Journal:  Asia Pac J Clin Oncol       Date:  2017-11-10       Impact factor: 2.601

5.  A regulatory circuit HP1γ/miR-451a/c-Myc promotes prostate cancer progression.

Authors:  C Chang; J Liu; W He; M Qu; X Huang; Y Deng; L Shen; X Zhao; H Guo; J Jiang; X Y Fu; R Huang; D Zhang; J Yan
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

6.  Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway.

Authors:  Shen Shen; Dylan C Dean; Zujiang Yu; Zhenfeng Duan
Journal:  Hepatol Res       Date:  2019-05-26       Impact factor: 4.288

7.  miR-139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF-4 pathway.

Authors:  Wei Gu; Xiaomei Li; Jue Wang
Journal:  Oncol Rep       Date:  2013-11-01       Impact factor: 3.906

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  CBX3/HP1γ is upregulated in tongue squamous cell carcinoma and is associated with an unfavorable prognosis.

Authors:  Huayong Zhang; Xiaoyan Fu; Xuan Su; Ankui Yang
Journal:  Exp Ther Med       Date:  2018-03-20       Impact factor: 2.447

10.  MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway.

Authors:  Jie Bao; Yan Yu; Jianan Chen; Yuting He; Xiaolong Chen; Zhigang Ren; Chen Xue; Liwen Liu; Qiuyue Hu; Juan Li; Guangying Cui; Ranran Sun
Journal:  Cell Death Dis       Date:  2018-10-12       Impact factor: 8.469

View more
  1 in total

1.  Expression and Prognostic Value of Chromobox Family Proteins in Esophageal Cancer.

Authors:  Jin Liu; Haixiang Shen; Xiangliu Chen; Yongfeng Ding; Haiyong Wang; Nong Xu; Lisong Teng
Journal:  Genes (Basel)       Date:  2022-09-03       Impact factor: 4.141

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.